

Mark K Louder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1216633/publications.pdf>

Version: 2024-02-01

59
papers

14,285
citations

61984

43
h-index

144013

57
g-index

63
all docs

63
docs citations

63
times ranked

10901
citing authors

#	ARTICLE	IF	CITATIONS
1	Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. <i>Science</i> , 2010, 329, 856-861.	12.6	1,600
2	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , 2020, 586, 567-571.	27.8	1,153
3	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. <i>Nature</i> , 2013, 496, 469-476.	27.8	961
4	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , 2020, 383, 1544-1555.	27.0	936
5	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. <i>Nature</i> , 2011, 480, 336-343.	27.8	794
6	Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing. <i>Science</i> , 2011, 333, 1593-1602.	12.6	788
7	Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. <i>Nature</i> , 2012, 491, 406-412.	27.8	753
8	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. <i>Nature</i> , 2014, 514, 455-461.	27.8	702
9	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , 2014, 509, 55-62.	27.8	681
10	Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. <i>Nature Structural and Molecular Biology</i> , 2015, 22, 522-531.	8.2	333
11	Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies. <i>Immunity</i> , 2013, 39, 245-258.	14.3	332
12	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. <i>Science</i> , 2016, 352, 828-833.	12.6	310
13	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. <i>Cell</i> , 2015, 161, 1280-1292.	28.9	305
14	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016, 165, 449-463.	28.9	305
15	Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. <i>Immunity</i> , 2016, 45, 1108-1121.	14.3	304
16	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. <i>Nature Medicine</i> , 2018, 24, 857-867.	30.7	256
17	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i> . <i>Journal of Virology</i> , 2014, 88, 12669-12682.	3.4	248
18	Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. <i>Cell</i> , 2015, 161, 470-485.	28.9	226

#	ARTICLE	IF	CITATIONS
19	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. <i>Science</i> , 2017, 358, 85-90.	12.6	225
20	Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization. <i>Science</i> , 2013, 340, 751-756.	12.6	213
21	Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	212
22	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , 2016, 90, 76-91.	3.4	205
23	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 81-90.	8.2	162
24	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. <i>Cell Reports</i> , 2017, 19, 719-732.	6.4	160
25	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005520.	4.7	150
26	The Development of CD4 Binding Site Antibodies during HIV-1 Infection. <i>Journal of Virology</i> , 2012, 86, 7588-7595.	3.4	123
27	Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes. <i>Journal of Virology</i> , 2015, 89, 2659-2671.	3.4	123
28	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. <i>Science Immunology</i> , 2017, 2, .	11.9	119
29	Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability. <i>Immunity</i> , 2019, 51, 915-929.e7.	14.3	111
30	Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. <i>Nature Chemical Biology</i> , 2017, 13, 1115-1122.	8.0	110
31	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. <i>Cell</i> , 2019, 178, 567-584.e19.	28.9	106
32	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	87
33	Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop. <i>Immunity</i> , 2017, 46, 777-791.e10.	14.3	81
34	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	81
35	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. <i>Immunity</i> , 2019, 50, 677-691.e13.	14.3	77
36	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. <i>Nature Communications</i> , 2017, 8, 1732.	12.8	76

#	ARTICLE	IF	CITATIONS
37	HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes. <i>Journal of Virology</i> , 2012, 86, 3393-3397.	3.4	71
38	Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. <i>Structure</i> , 2019, 27, 196-206.e6.	3.3	69
39	A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope. <i>Immunity</i> , 2018, 48, 500-513.e6.	14.3	66
40	Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity. <i>Nature Communications</i> , 2018, 9, 877.	12.8	65
41	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. <i>Journal of Virology</i> , 2016, 90, 5899-5914.	3.4	62
42	HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins. <i>Journal of Virology</i> , 2012, 86, 11231-11241.	3.4	61
43	Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. <i>Cell Reports</i> , 2020, 31, 107488.	6.4	53
44	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. <i>Cell Reports</i> , 2018, 22, 1798-1809.	6.4	52
45	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. <i>PLoS Pathogens</i> , 2017, 13, e1006148.	4.7	51
46	Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry. <i>Nature Communications</i> , 2019, 10, 47.	12.8	50
47	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , 2021, 371, .	12.6	49
48	N332-Directed Broadly Neutralizing Antibodies Use Diverse Modes of HIV-1 Recognition: Inferences from Heavy-Light Chain Complementmentation of Function. <i>PLoS ONE</i> , 2013, 8, e55701.	2.5	38
49	Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding. <i>Journal of Virology</i> , 2016, 90, 10574-10586.	3.4	35
50	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. <i>Nature Communications</i> , 2019, 10, 2898.	12.8	35
51	Improvement of antibody functionality by structure-guided paratope engraftment. <i>Nature Communications</i> , 2019, 10, 721.	12.8	27
52	VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage. <i>Cell Host and Microbe</i> , 2020, 27, 531-543.e6.	11.0	23
53	Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	21
54	High throughput HIV-1 microneutralization assay. <i>Protocol Exchange</i> , 0, , .	0.3	16

#	ARTICLE	IF	CITATIONS
55	A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. <i>MAbs</i> , 2021, 13, 1946918.	5.2	11
56	Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations. <i>Cell Reports</i> , 2021, 36, 109561.	6.4	9
57	Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces. <i>Nature Communications</i> , 2021, 12, 6470.	12.8	3
58	Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2. <i>Advanced Science</i> , 2022, , 2200063.	11.2	3
59	^Rapid Selection of HIV Envelopes that Bind to Neutralizing Antibody B Cell Lineage Members with Functional Improbable Mutations. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1